Zai gains Hong Kong approval of PARP inhibitor Zejula

Zai Lab Ltd. (NASDAQ:ZLAB) is preparing for its first product launch after Hong Kong's Department of Health approved its PARP inhibitor Zejula niraparib to treat platinum-sensitive, relapsed ovarian cancer in adults who are in complete or partial response to platinum-based chemotherapy. The company said Zejula is the first PARP inhibitor to gain Hong Kong approval in the maintenance setting irrespective of BRCA mutation status.

Zai intends to launch Zejula in Hong Kong this quarter. The company has rights to the drug from Tesaro Inc.(NASDAQ:TSRO), which markets it in the U.S. and EU in the maintenance setting...